New drug aims to stop repeat heart attacks by calming inflammation
Disease control
Recruiting now
This study tests a drug called ziltivekimab in people who recently had a heart attack. The goal is to see if it can reduce dangerous fatty plaques in the arteries by lowering inflammation. About 332 participants will receive either the drug or a placebo, plus standard care, for 1…
Phase: PHASE3 • Sponsor: ECRI bv • Aim: Disease control
Last updated May 17, 2026 13:27 UTC